Meningioma and gliomas
Conditions
Interventions
A:Iv a dose of 1U hemocoagulase before operation 30min ago, local use with Gelfoam (2U hemocoagulase +10 ml saline) by infiltration, a dose of 1U hemocoagulase after
B:Iv a dose of 2U hemocoagulase before operation 30min ago, local use with Gelfoam (4U hemocoagulase +10 ml saline) by infiltration, a dose of 2U hemocoagulase after
C:None Hemostatic drug
Sponsors
China Nuokang Bio-pharmaceutical INC.
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old , sex is not limited; 2. Neurosurgery elective patients with meningioma or glioma patient, (ASA) score I-II level; 3. 2-6cm convexity meningioma or single supratentorial gliomas; 4. Agree to Surgical indications of Heart & lung and without the coagulation system disease; 5. Hb, PLT, PT, INR, APTT agree to Surgical indications; 6. Able and willing to provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Irritable the physique or allergy to hemocoagulase Atrox; 2. Had use drug about coagulation system in two weeks, such as Aspirin, clopidogrel, Ticlopidine, Dipyridamole, Ginkgo Bi loba Leaf, heparin, Warfarin, citrate, hemocoagulase Atrox, Vk, Anti- fibrinolytics, Etamsvlatum, Vc; 3. Metastatic Tumors; 4. Systemic disease such as un-controlled hypertension, TB, un-controlled diabetes, un-controlled Hepatology, other diseases may interfere with study participation or evaluation; 5. Anaemia or disturbance of blood coagulation; 6. History of thrombosis or thrombophilia by checked or serious blood disorders; 7. Pregnant or lactating women; 8. Have join in other clinical study in four weeks; 9. Poor compliance; 10. Researcher think who can't complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemorrhage volume in operation; | — |
Countries
China
Contacts
Public ContactBin Zhou
Outcome results
None listed